Novel Delta-Opioid Receptor Agonist PN6047 Shows Promise in Preclinical Headache Models
A preclinical study published on bioRxiv found that PN6047, a novel delta-opioid receptor (DOR) agonist, effectively reduced pain and aura-related measures across multiple mouse models of migraine, post-traumatic headache, and medication overuse headache. Unlike many existing treatments, chronic PN6047 administration did not itself induce medication overuse headache or analgesic tolerance in the tested animals. The findings are significant because they suggest DOR agonism may offer a safer therapeutic profile than current migraine treatments, particularly for patients at risk of medication overuse.
Researchers tested PN6047, a novel delta-opioid receptor (DOR) agonist, across four preclinical mouse models relevant to migraine and headache disorders: chronic intermittent nitroglycerin-induced migraine pain, post-traumatic headache, KCl-induced cortical spreading depression (CSD), and optogenetically evoked CSD in freely behaving transgenic mice. A single injection of PN6047 was sufficient to block established cephalic allodynia in both the nitroglycerin and post-traumatic headache models. In CSD experiments — a neurological phenomenon underlying migraine aura — PN6047 significantly reduced the number of CSD events and delayed their onset, while also attenuating subsequent CSD-evoked allodynia. Critically, chronic PN6047 treatment prevented the development of medication overuse headache (MOH) induced by sumatriptan, and prolonged use of PN6047 itself did not cause MOH or analgesic tolerance. The compound has already completed a Phase I clinical trial with a reported favorable safety and tolerability profile, lending additional translational relevance to these animal findings. The DOR target is of particular interest because it is thought to carry lower abuse liability and reduced physical dependence risk compared to mu-opioid receptor agonists. The study was posted as a preprint on bioRxiv and has not yet undergone formal peer review.
What different sources said
- bioRxivCenter
PN6047 Demonstrates Broad Preclinical Efficacy in Headache Models as a Novel Delta-Opioid Receptor Agonist
Related
Multiscale Brain Model Predicts Novel Propofol Anesthesia Biomarker Without Training on Clinical Data
Researchers developed a mechanistic computational model of thalamocortical brain circuits that successfully predicted a previously unnoticed dose-dependent biomarker of propofol anesthesia. The model, driven solely by GABA-A receptor modulation, reproduced empirical data from both macaques and humans without being fitted to any anesthesia-specific data. The findings suggest that simulation-first approaches could accelerate biomarker discovery in neuropharmacology without requiring large clinical datasets.
Green-Synthesized Zinc Oxide Nanoparticles from Mimosa pudica Show Biocompatibility with Bone Marrow Stem Cells in Lab Study
Researchers synthesized zinc oxide nanoparticles using Mimosa pudica leaf extract and tested their effects on human bone marrow mesenchymal stromal cells, finding the nanoparticles preserved cell viability, structure, and bone-forming capacity. The plant-derived nanoparticles outperformed both the raw plant extract and conventionally synthesized zinc oxide in maintaining cell metabolic activity over five days. The findings suggest these bioactive nanomaterials could be candidates for musculoskeletal tissue engineering, though the research remains at an early in vitro stage.
Study Compares Genetic Modeling Approaches for Dyadic Social Interactions in Animals
A new preprint study compared two statistical modeling approaches for analyzing the genetic basis of social interactions in animals, finding that dyadic models outperform marginal models that aggregate individual-level data. The research used pig aggression data from 797 finishing pigs across 59 social groups as a test case. The findings have implications for how animal geneticists model and interpret the heritable components of social behavior.